Skip to content

Study · Systematic review · n = 3,613 · 2022

5 results

Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.

Tan HC, Dampil OA, Marquez MM

Journal of the ASEAN Federation of Endocrine Societies23 Aug 2022Cited by 75 (Europe PMC)

PMID36578889 (opens in a new tab)PMCIDPMC9758543 (opens in a new tab)DOI10.15605/jafes.037.02.14 (opens in a new tab)PepBankPUB-36578889
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with obesity without diabetes, subcutaneous semaglutide reduced body weight more than placebo in a meta-analysis.

    In plain wordsIn pooled trials of adults with obesity without diabetes, injected semaglutide led to more weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction (percent mean difference)
    Study

    n = 3,613

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    mean difference in weight
    −11.85%
    semaglutide vs placebo

    Source sentences

    Summary
    The mean difference for weight reduction was -11.85%, favoring semaglutide [95% confidence interval (CI) (-12.81,-10.90), p<0.00001].
    2 context sentences
    Summary · context
    Among individuals with obesity without type 2 diabetes, subcutaneous semaglutide is effective for weight loss with an 11.85% reduction from baseline compared to placebo.
    Summary · context
    A comprehensive search of PubMed/MEDLINE, Cochrane and Google scholar was performed to identify trials on the efficacy and safety of subcutaneous semaglutide on patients with obesity without diabetes.
  2. 02HumanSystematic reviewSafety outcome

    In adults with obesity without diabetes, gastrointestinal adverse events were more likely with semaglutide than with placebo in a meta-analysis.

    In plain wordsIn pooled trials of adults with obesity without diabetes, digestive side effects were more likely with semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n = 3,613

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    RR
    1.59 ratio
    GI adverse events vs placebo

    Source sentences

    Summary
    Secondary outcomes showed that the risk of developing gastrointestinal adverse events was 1.59 times more likely with semaglutide (RR 1.59, 95%CI [1.34, 1.88], p<0.00001).
    2 context sentences
    Summary · context
    However, risk of gastrointestinal adverse events, discontinuation of treatment and serious adverse events were higher in the semaglutide group versus placebo.
    Summary · context
    A comprehensive search of PubMed/MEDLINE, Cochrane and Google scholar was performed to identify trials on the efficacy and safety of subcutaneous semaglutide on patients with obesity without diabetes.
  3. 03HumanSystematic reviewSafety outcome

    In adults with obesity without diabetes, discontinuation due to adverse events was more likely with semaglutide than with placebo in a meta-analysis.

    In plain wordsIn pooled trials of adults with obesity without diabetes, people were more likely to stop semaglutide than placebo because of side effects.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiscontinuation due to adverse events
    Study

    n = 3,613

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    RR
    2.19 ratio
    discontinuation vs placebo

    Source sentences

    Summary
    Risk for discontinuation due to adverse events was twice as likely in the semaglutide group (RR 2.19, 95%CI [1.36,3.55], p=0.001)
    2 context sentences
    Summary · context
    However, risk of gastrointestinal adverse events, discontinuation of treatment and serious adverse events were higher in the semaglutide group versus placebo.
    Summary · context
    A comprehensive search of PubMed/MEDLINE, Cochrane and Google scholar was performed to identify trials on the efficacy and safety of subcutaneous semaglutide on patients with obesity without diabetes.
  4. 04HumanSystematic reviewSafety outcome

    In adults with obesity without diabetes, serious adverse events were more likely with semaglutide than with placebo in a meta-analysis.

    In plain wordsIn pooled trials of adults with obesity without diabetes, serious adverse events were more likely with semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseSerious adverse events
    Study

    n = 3,613

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    RR
    1.6 ratio
    serious adverse events vs placebo

    Source sentences

    Summary
    the risk for serious adverse events was 1.6 times more likely for semaglutide (RR1.60, 95%CI [1.24, 2.07], p=0.0003).
    2 context sentences
    Summary · context
    However, risk of gastrointestinal adverse events, discontinuation of treatment and serious adverse events were higher in the semaglutide group versus placebo.
    Summary · context
    A comprehensive search of PubMed/MEDLINE, Cochrane and Google scholar was performed to identify trials on the efficacy and safety of subcutaneous semaglutide on patients with obesity without diabetes.
  5. 05HumanSystematic reviewSafety outcome

    In adults with obesity without diabetes, serious events with semaglutide were mostly gastrointestinal and hepatobiliary disorders such as acute pancreatitis and cholelithiasis.

    In plain wordsIn pooled trials of adults with obesity without diabetes, serious events with semaglutide were mostly digestive and liver or gallbladder disorders.

    Peptide
    Semaglutide
    Outcome
    Not applicableTypes of serious adverse events
    Study

    n = 3,613

    Analysis
    Secondary
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Serious events were mostly of gastrointestinal and hepatobiliary disorders such as acute pancreatitis and cholelithiasis.
    1 context sentence
    Summary · context
    A comprehensive search of PubMed/MEDLINE, Cochrane and Google scholar was performed to identify trials on the efficacy and safety of subcutaneous semaglutide on patients with obesity without diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 4NCT07513168

Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

Asian Institute Of Medical Sciencesn = 601 Aug 2025 to est. 1 Dec 2026

Obesity · Weight Reduction · Cardiometabolic Risk Factors

Trial pageClinicalTrials.govUpdated 6 Apr 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.